Cloud Pharmaceuticals Strengthens Management Teamwith Appointment of Two C-Level Executives

Cloud Pharmaceuticals Strengthens Management Team
with Appointment of Two C-Level Executives

Lyle Lohmeyer Joins as Chief Financial Officer,
Don Van Dyke Becomes Chief Operating Officer

RESEARCH TRIANGLE PARK, NC (August 17, 2015)…Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, today announced the appointment of two C-level executives to its management team. Lyle Lohmeyer joins the company as its CFO and Don Van Dyke has been appointed COO.

"The appointments of Lyle and Don reflect Cloud Pharmaceuticals' strengthened position as a pioneer of cloud-based drug discovery," says Addison. "With Lyle's oversight, we can pursue continued growth while maintaining fiscal responsibility. Don applies more than 20 years of business development experience in the life sciences industry, including time spent as a CEO of early-stage companies. Both offer expertise to help ensure that we deliver ongoing value to our customers, business partners, and investors."

Lyle Lohmeyer
Chief Financial Officer


Lohmeyer has extensive experience as a financial executive with specific expertise in M&A, fundraising, debt control and administration, and operations management industries such as pharmaceutical services, clinical research, electronics, software, and manufacturing. At Cloud Pharmaceuticals, Lohmeyer's responsibilities include financial management, fundraising, and business development.

Previously, Lohmeyer held financial management positions with companies such as AAIPharma, Qualia Networks, Energy Conversion Systems Holdings, Abaco Mobile and NAVTEQ. He started his career with PricewaterhouseCoopers in Chicago. He holds a BSGM in accounting and finance from Purdue University's Krannert School of Management and a Masters of Management from Northwestern University's Kellogg School of Management. He is also a certified public accountant.

Don Van Dyke
Chief Operating Officer


Van Dyke has been appointed to the role of chief operating officer. He was previously a consultant to the company and its director of marketing and business development. In his new role, Van Dyke is focusing on the business operations of the company. In addition, he is overseeing the company's marketing and business development efforts.

Van Dyke has held general management, business development, and sales and marketing positions throughout his career with companies such as American Hospital Supply, Eastman Kodak, and Millipore. He has built organizations from the ground up, beginning at startup Bio Image Corporation in various executive roles and ultimately CEO. He has held VP-level roles at Molecular Mining Corp. and INCOGEN and has advised more than a dozen startups and government agencies. Van Dyke has been an invited speaker at the Mason School of Business at the College of William and Mary and the Kenan-Flagler Business School at the University of North Carolina. He is a graduate of Duke University.

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners. For information visit www.cloudpharmaceuticals.com.

###

Company Contact: Media Contact:

Don Van Dyke, COO
Cloud Pharmaceuticals
[email protected]com 
 
 

Carol Long, Principal
CDL Communications
[email protected]

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.